NCT04578613 2023-06-05
ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
Clinical Trials
10 trialsNCT05287984 2022-03-31
ZFCR/ZBR
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT01619761 2020-02-11
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT02315118 2016-06-22
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies
National University Hospital, Singapore
Phase 1/2 Unknown
NCT01521689 2015-03-20
LLCRlowdoz
Institut Paoli-Calmettes
Phase 2 Unknown
NCT02156726 2014-06-05
Q-lite
Czech CLL Study Group
Unknown
NCT01670812 2012-08-22
Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Unknown
NCT00628238 2010-09-10
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia Research Consortium
Phase 2 Unknown
NCT00927797 2009-06-25
PERLL
Heidelberg University
Phase 2 Unknown
NCT00131313 2005-08-18
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
East Valley Hematology and Oncology Medical Group
Phase 4 Unknown